Results 11 to 20 of about 4,204,651 (354)
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
Lancet, The, 2017 A. Balar, M. Galsky, J. Rosenberg, T. Powles, D. Petrylak, J. Bellmunt, Y. Loriot, A. Necchi, J. Hoffman-Censits, J. Pérez-Gracia, N. Dawson, M. S. van der Heijden, R. Dreicer, S. Srinivas, M. Retz, R. Joseph, A. Drakaki, U. Vaishampayan, S. Sridhar, D. Quinn, I. Durán, D. Shaffer, B. Eigl, P. Grivas, E. Yu, Shi Li, E. Kadel, Z. Boyd, R. Bourgon, P. Hegde, S. Mariathasan, A. Thåström, O. Abidoye, G. Fine, D. Bajorin +34 moresemanticscholar +3 more sourcesAtezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.
Lancet, The, 2018 T. Powles, I. Durán, M. S. van der Heijden, Y. Loriot, N. Vogelzang, U. de Giorgi, S. Oudard, M. Retz, D. Castellano, A. Bamias, A. Fléchon, G. Gravis, S. Hussain, T. Takano, Ning Leng, E. Kadel, R. Banchereau, P. Hegde, S. Mariathasan, N. Cui, Xiao-dong Shen, C. Derleth, Marjorie C. Green, A. Ravaud +23 moresemanticscholar +3 more sourcesPreoperative Treatment of Locally Advanced Rectal Cancer.
New England Journal of Medicine, 2023 BACKGROUND
Pelvic radiation plus sensitizing chemotherapy with a fluoropyrimidine (chemoradiotherapy) before surgery is standard care for locally advanced rectal cancer in North America. Whether neoadjuvant chemotherapy with fluorouracil, leucovorin, and D. Schrag, Q. Shi, M. Weiser, M. Gollub, L. Saltz, Benjamin L. Musher, Joel E. Goldberg, T. Al Baghdadi, K. Goodman, R. McWilliams, J. Farma, T. George, H. Kennecke, A. Shergill, M. Montemurro, G. Nelson, B. Colgrove, V. Gordon, A. Venook, E. O’Reilly, J. Meyerhardt, A. Dueck, E. Basch, G. Chang, H. Mamon +24 moresemanticscholar +1 more sourceMulticenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma
Journal for ImmunoTherapy of Cancer, 2022 Background Camrelizumab and chemotherapy demonstrated durable antitumor activity with a manageable safety profile as first-line treatment in patients with advanced esophageal squamous cell carcinoma (ESCC).Jun Liu, Yang Yang, Zhichao Liu, Xiao-long Fu, X. Cai, Hong-xuan Li, Li Zhu, Yan Shen, Hong Zhang, Yifeng Sun, Hezhong Chen, Bentong Yu, Renquan Zhang, J. Shao, Ming Zhang, Zhigang Li +15 moresemanticscholar +1 more sourceManagement of Locally Advanced Esophageal Cancer
Journal of Nepal Medical Association, 2021 Esophageal cancer is diagnosed usually at a locally advanced stage. Surgery alone has less optimal results and a multimodality approach has been established as the standard of care for cII-III stages of esophageal cancer.Binay Thakur, Mukti Devkota, Manish Chaudhary +2 moredoaj +3 more sourcesEfficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials
Journal of Clinical Oncology, 2023 PURPOSE To evaluate the efficacy and safety of disitamab vedotin (DV, RC48-ADC), a novel humanized anti–human epidermal growth factor receptor 2 (HER2) antibody conjugated with monomethyl auristatin E, in patients with HER2-positive locally advanced or ...X. Sheng, Lin Wang, Zhi-cong He, Yanxia Shi, Hong Luo, W. Han, Xin Yao, Benkang Shi, Jiyan Liu, Changlu Hu, Ziling Liu, Hongqian Guo, G. Yu, Z. Ji, J. Ying, Y. Ling, Shiying Yu, Yi Hu, Jianming Guo, J. Fang, Aiping Zhou, Jun Guo +21 moresemanticscholar +1 more sourceOptimizing CIGB-300 intralesional delivery in locally advanced cervical cancer [PDF]
, 2015 Background:We conducted a phase 1 trial in patients with locally advanced cervical cancer by injecting 0.5 ml of the CK2-antagonist CIGB-300 in two different sites on tumours to assess tumour uptake, safety, pharmacodynamic activity and identify the ...A Perera, A Prats, A Rodriguez-Ulloa, A Siddiqui-Jain, AM Solares, B E Acevedo, C A Casacó, C M Valenzuela, CA Naranjo, D F Alonso, F Piazza, I Baladrón, I García, I Hernández, J A Ancízar, JA Siegel, JL Soriano-García, JS Duncan, KA Ahmad, L A Torres, L González, L Molina, M A Coca, M R Sarduy, M Solares, P A López-Saura, P Therasse, R Gómez, R Prudent, RE Carter, S E Perea-Rodríguez, S Tawfic, SE Perea, SE Perea, SE Perea, V Reyes, Y M González, Y M Martínez, Y Perera, Y Perera, Y Perera, Y Perera +41 morecore +2 more sourcesPemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
The Lancet Oncology, 2020 BACKGROUND
Fibroblast growth factor receptor (FGFR) 2 gene alterations are involved in the pathogenesis of cholangiocarcinoma. Pemigatinib is a selective, potent, oral inhibitor of FGFR1, 2, and 3.G. Abou-Alfa, V. Sahai, A. Hollebecque, G. Vaccaro, D. Melisi, R. Al-Rajabi, A. Paulson, M. Borad, D. Gallinson, A. Murphy, D. Oh, E. Dotan, D. Catenacci, E. Van Cutsem, T. Ji, C. Lihou, H. Zhen, L. Féliz, A. Vogel +18 moresemanticscholar +1 more sourceEfficacy and Safety of Intraoperative Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Colon Cancer: A Phase 3 Randomized Clinical Trial.
JAMA Surgery, 2023 Importance
Peritoneal metastasis in patients with locally advanced colon cancer (T4 stage) is estimated to recur at a rate of approximately 25% at 3 years from surgical resection and is associated with poor prognosis.Á. Arjona-Sánchez, E. Espinosa-Redondo, A. Gutiérrez-Calvo, J. Segura-Sampedro, E. Pérez-Viejo, Vanessa Concepción-Martín, S. Sánchez-García, A. García-Fadrique, I. Prieto-Nieto, P. Barrios-Sánchez, J. Torres‐Melero, M. Ramirez Faraco, A. Prada-Villaverde, J. Carrasco-Campos, M. Artiles-Armas, P. Villarejo-Campos, G. Ortega-Pérez, E. Boldo-Roda, J. Sánchez-Hidalgo, Á. Casado-Adam, L. Rodriguez-Ortiz, E. Aranda, M. Cano‐Osuna, César Díaz-López, A. Romero-Ruiz, J. Briceño-Delgado, S. Rufián-Peña +26 moresemanticscholar +1 more source
